Research programme: rheumatoid arthritis therapy - MediGene AGAlternative Names: EndoMTX
Latest Information Update: 30 Aug 2010
At a glance
- Originator MediGene AG
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 04 Feb 2007 Preclinical trials in Rheumatoid arthritis in Germany (unspecified route)